HC Wainwright Comments on Savara Inc’s FY2025 Earnings (NASDAQ:SVRA)

Savara Inc (NASDAQ:SVRA) – Analysts at HC Wainwright reduced their FY2025 EPS estimates for Savara in a research note issued to investors on Thursday, June 27th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.43) for the year, down from their previous forecast of ($0.38). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Savara’s FY2026 earnings at ($0.27) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.44 EPS.

Several other brokerages have also recently issued reports on SVRA. Evercore ISI dropped their target price on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, May 16th. JMP Securities restated a “market outperform” rating and issued a $8.00 target price on shares of Savara in a report on Monday, May 6th. Oppenheimer raised their target price on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a report on Wednesday, June 26th. Finally, Guggenheim raised their target price on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $11.00.

Savara Price Performance

Shares of SVRA opened at $4.30 on Monday. Savara has a twelve month low of $2.93 and a twelve month high of $5.70. The company has a quick ratio of 14.90, a current ratio of 14.90 and a debt-to-equity ratio of 0.22. The firm has a 50 day moving average of $4.29 and a 200 day moving average of $4.64. The company has a market capitalization of $594.22 million, a P/E ratio of -11.62 and a beta of 1.00.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SVRA. Jennison Associates LLC boosted its stake in shares of Savara by 128.0% during the 4th quarter. Jennison Associates LLC now owns 8,815,358 shares of the company’s stock worth $41,432,000 after acquiring an additional 4,948,596 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Savara during the 4th quarter worth $9,683,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of Savara by 30.9% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock worth $30,008,000 after acquiring an additional 1,874,000 shares during the last quarter. Polar Capital Holdings Plc purchased a new position in shares of Savara during the 3rd quarter worth $3,780,000. Finally, Opaleye Management Inc. purchased a new position in shares of Savara during the 1st quarter valued at $4,258,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.